This inventor holds 23 USPTO granted patents and 11 published patent applications, plus 8 CIPO patents and 15 EPO patents, primarily in Metalloenzyme Inhibitors. Top assignees: Viamet Pharmaceuticals, Inc., Mycovia Pharmaceuticals, Inc., Innocrin Pharmaceuticals, Inc.. Active years: 2012-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
17 out of 23 
4 out of 21 
2 out of 2 Years Active: 2012-2022
Areas of Expertise:
Title: Robert J. Schotzinger: Innovator in Drug Development
Introduction
Robert J. Schotzinger is a prominent inventor based in Raleigh, NC, who holds an impressive portfolio of 23 patents. His innovative contributions primarily focus on developing compounds that have significant implications in the fields of biochemistry and pharmaceutical science. With a solid background working in leading pharmaceutical companies, Schotzinger has made a lasting impact on the industry.
Latest Patents
Among his latest patents is a groundbreaking invention related to metalloenzyme inhibitor compounds. This invention describes compounds that exhibit metalloenzyme modulating activity and outlines methods to treat various diseases, disorders, or symptoms that are mediated by such metalloenzymes. Additionally, Schotzinger has developed antifungal compounds defined by a specific chemical formula. These compounds act as inhibitors of essential metalloenzymes, such as lanosterol demethylase (CYP51), showcasing his dedication to advancing therapeutic strategies.
Career Highlights
Throughout his career, Schotzinger has contributed his expertise to renowned firms in the pharmaceutical industry, including Viamet Pharmaceuticals and Mycovia Pharmaceuticals. His work has positioned him as a notable figure within the realm of pharmaceutical inventions, driving forward innovative solutions to complex health challenges.
Collaborations
Robert has collaborated with various distinguished professionals in the field, including William Joel Hoekstra and Stephen William Rafferty. These collaborations reflect his commitment to fostering innovation and enhancing the development of new therapeutic agents.
Conclusion
Robert J. Schotzinger continues to be a significant force in the pharmaceutical landscape, leveraging his extensive patent portfolio to influence drug development and treatment methodologies. His contributions not only demonstrate his expertise but also highlight the transformative potential of innovations within the healthcare sector.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile